CARFILZOMIB INJ
Clinical Criteria Summary
Exclusion Criteria
- Absolute neutrophil count < 1000/µL and/or platelet count < 50,000/µL (<30,000/mm³ if myeloma involvement in bone marrow > 50%)
- Total bilirubin > 1.5x upper limit of normal (unless Gilbert’s syndrome or liver involvement) and/or alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase > 3x upper limit of normal (unless liver involvement)
- Clinically significant cardiovascular disease, including: baseline left ventricular ejection fraction < 50% via MUGA or echocardiography; uncontrolled hypertension or arrhythmia; myocardial infarction within prior 6 months; symptomatic congestive heart failure (New York Heart Assoc Class 3-4)
- Grade 3 or 4 peripheral neuropathy
- Active or uncontrolled infection
- Unmanageable drug-drug interaction
- Known pregnancy
- Lactating
Inclusion Criteria
- Previously treated multiple myeloma
- Care provided by a VA/VA Community Care oncology or hematology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Goals of care and role of Palliative Care consult have been discussed and documented
- Venous thromboembolism (VTE) risk scoring (i.e. SAVED, IMPEDE) performed for consideration of VTE prophylaxis
Additional Inclusion Criteria
- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and use of effective contraception during therapy and for 6 months after stopping treatment
- For patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and use of effective contraception during therapy and for 3 months after stopping treatment